Imugene Generates income of $5.34m in H1 FY22
- Imugene (IMU) records an income of more than $5.34 million for the half-year ending December 31, 2021, up from the $4.11 million in the prior corresponding period
- The company posted a loss of $14.8 million, up from the previous $6.04 million, due to the significant increase in clinical trial and research activities undertaken
- In November, the platform entered a supply agreement with Merck Darmstadt and Pfizer to evaluate the safety and efficacy of its HER-Vaxx immunotherapy with chemotherapy
- The company also used the half to recruit patients for its study of PD1-Vaxx in patients with non-small cell lung cancer
- IMU shares steady at 23.5 cents
